Cargando…
Stencil Printing—A Novel Manufacturing Platform for Orodispersible Discs
Stencil printing is a commonly used printing method, but it has not previously been used for production of pharmaceuticals. The aim of this study was to explore whether stencil printing of drug containing polymer inks could be used to manufacture flexible dosage forms with acceptable mass and conten...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023198/ https://www.ncbi.nlm.nih.gov/pubmed/31906316 http://dx.doi.org/10.3390/pharmaceutics12010033 |
_version_ | 1783498194318000128 |
---|---|
author | Wickström, Henrika Koppolu, Rajesh Mäkilä, Ermei Toivakka, Martti Sandler, Niklas |
author_facet | Wickström, Henrika Koppolu, Rajesh Mäkilä, Ermei Toivakka, Martti Sandler, Niklas |
author_sort | Wickström, Henrika |
collection | PubMed |
description | Stencil printing is a commonly used printing method, but it has not previously been used for production of pharmaceuticals. The aim of this study was to explore whether stencil printing of drug containing polymer inks could be used to manufacture flexible dosage forms with acceptable mass and content uniformity. Formulation development was supported by physicochemical characterization of the inks and final dosage forms. The printing of haloperidol (HAL) discs was performed using a prototype stencil printer. Ink development comprised of investigations of ink rheology in combination with printability assessment. The results show that stencil printing can be used to manufacture HAL doses in the therapeutic treatment range for 6–17 year-old children. The therapeutic HAL dose was achieved for the discs consisting of 16% of hydroxypropyl methylcellulose (HPMC) and 1% of lactic acid (LA). The formulation pH remained above pH 4 and the results imply that the drug was amorphous. Linear dose escalation was achieved by an increase in aperture area of the print pattern, while keeping the stencil thickness fixed. Disintegration times of the orodispersible discs printed with 250 and 500 µm thick stencils were below 30 s. In conclusion, stencil printing shows potential as a manufacturing method of pharmaceuticals. |
format | Online Article Text |
id | pubmed-7023198 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-70231982020-03-12 Stencil Printing—A Novel Manufacturing Platform for Orodispersible Discs Wickström, Henrika Koppolu, Rajesh Mäkilä, Ermei Toivakka, Martti Sandler, Niklas Pharmaceutics Article Stencil printing is a commonly used printing method, but it has not previously been used for production of pharmaceuticals. The aim of this study was to explore whether stencil printing of drug containing polymer inks could be used to manufacture flexible dosage forms with acceptable mass and content uniformity. Formulation development was supported by physicochemical characterization of the inks and final dosage forms. The printing of haloperidol (HAL) discs was performed using a prototype stencil printer. Ink development comprised of investigations of ink rheology in combination with printability assessment. The results show that stencil printing can be used to manufacture HAL doses in the therapeutic treatment range for 6–17 year-old children. The therapeutic HAL dose was achieved for the discs consisting of 16% of hydroxypropyl methylcellulose (HPMC) and 1% of lactic acid (LA). The formulation pH remained above pH 4 and the results imply that the drug was amorphous. Linear dose escalation was achieved by an increase in aperture area of the print pattern, while keeping the stencil thickness fixed. Disintegration times of the orodispersible discs printed with 250 and 500 µm thick stencils were below 30 s. In conclusion, stencil printing shows potential as a manufacturing method of pharmaceuticals. MDPI 2020-01-01 /pmc/articles/PMC7023198/ /pubmed/31906316 http://dx.doi.org/10.3390/pharmaceutics12010033 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wickström, Henrika Koppolu, Rajesh Mäkilä, Ermei Toivakka, Martti Sandler, Niklas Stencil Printing—A Novel Manufacturing Platform for Orodispersible Discs |
title | Stencil Printing—A Novel Manufacturing Platform for Orodispersible Discs |
title_full | Stencil Printing—A Novel Manufacturing Platform for Orodispersible Discs |
title_fullStr | Stencil Printing—A Novel Manufacturing Platform for Orodispersible Discs |
title_full_unstemmed | Stencil Printing—A Novel Manufacturing Platform for Orodispersible Discs |
title_short | Stencil Printing—A Novel Manufacturing Platform for Orodispersible Discs |
title_sort | stencil printing—a novel manufacturing platform for orodispersible discs |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023198/ https://www.ncbi.nlm.nih.gov/pubmed/31906316 http://dx.doi.org/10.3390/pharmaceutics12010033 |
work_keys_str_mv | AT wickstromhenrika stencilprintinganovelmanufacturingplatformfororodispersiblediscs AT koppolurajesh stencilprintinganovelmanufacturingplatformfororodispersiblediscs AT makilaermei stencilprintinganovelmanufacturingplatformfororodispersiblediscs AT toivakkamartti stencilprintinganovelmanufacturingplatformfororodispersiblediscs AT sandlerniklas stencilprintinganovelmanufacturingplatformfororodispersiblediscs |